• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Gonsalves Rodney

    (Last) (First) (Middle)
    5301 STEVENS CREEK BLVD

    (Street)
    SANTA CLARA CA 95051

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AGILENT TECHNOLOGIES, INC. [ A ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    V.P., Corporate Controller
    3. Date of Earliest Transaction (Month/Day/Year)
    09/28/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/28/2023 P 2.59 A $111.09 24,221.5201 D
    Common Stock 40.192 I Gonsalves Trust(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares held by the Gonsalves Trust for which Rodney and Rochelle Gonsalves are the trustees.
    /s/ P. Diana Chiu, attorney-in-fact for Mr. Gonsalves 09/29/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    6/11/2026$150.00Neutral
    Piper Sandler
    5/28/2026$145.00Neutral → Buy
    BofA Securities
    5/27/2026$153.00Outperform
    RBC Capital Mkts
    1/20/2026$180.00Buy
    HSBC Securities
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    12/9/2025$170.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    More analyst ratings

    $A
    SEC Filings

    View All

    Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    6/25/26 4:23:06 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    6/1/26 4:09:02 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SD filed by Agilent Technologies Inc.

    SD - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    5/29/26 4:10:04 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies

    Denver, CO and London, UK – 25 June 2026: Excellere Partners ("Excellere"), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP ("GHO"), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical ("Biocare"), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. ((", Agilent", , NYSE:A). Under the stewardship of Excellere and GHO, the company delivered annual double-digit revenue and profitability growth, strengthened its core IHC business, expanded into molec

    6/25/26 8:06:05 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Completes Acquisition of Biocare Medical

    Highly complementary combination expands Agilent’s pathology portfolio and ability to serve customers across clinical and research settingsExpected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in the first yearAgilent Technologies Inc. (NYSE:A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group."We are pleased to complete our acquisition of Biocare, which repr

    6/25/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

    Agilent Technologies Inc. (NYSE:A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company's products, operations, and customer workflows. "AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation value for our customers," said Padraig McDonnell, president and CEO of Agilent. "Through this collaboration with OpenAI and BCG, we are accelerating deployment of AI across our business while advancing more intelligent instruments, soft

    6/3/26 7:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Financials

    Live finance-specific insights

    View All

    Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

    Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre

    5/27/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide tru

    5/20/26 4:27:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bloomberg Expands Global Equity Offering with Australia Domestic Equity Indices

    New indices deliver transparent, comprehensive access to Australian equities for benchmarking and investment applicationsNEW YORK and SYDNEY, April 28, 2026 /PRNewswire/ -- Bloomberg today announced the launch of the new Bloomberg Australia Domestic Equity Indices. The indices are designed to provide broad and investable exposure to Australian equities for benchmarking, asset allocation, and creation of financial products for both institutional and retail investors. "The launch of our Australia Domestic Equity Indices represents a natural evolution of our offering, building on a

    4/28/26 5:30:00 PM ET
    $A
    $AD
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Telecommunications Equipment
    Telecommunications

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Agilent with a new price target

    Piper Sandler initiated coverage of Agilent with a rating of Neutral and set a new price target of $150.00

    6/11/26 8:10:17 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by BofA Securities with a new price target

    BofA Securities upgraded Agilent from Neutral to Buy and set a new price target of $145.00

    5/28/26 8:43:55 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    RBC Capital Mkts initiated coverage on Agilent with a new price target

    RBC Capital Mkts initiated coverage of Agilent with a rating of Outperform and set a new price target of $153.00

    5/27/26 9:00:20 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Michael Buckner as Chief Legal Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. "We are thrilled to welcome Michael to the Agilent team," said Padraig McDonnell, Agilent president and CEO. "His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and

    5/4/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Cancer Research Solutions at AACR 2026

    Agilent Technologies Inc. (NYSE:A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum. Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode micropla

    4/15/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)

    3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/5/26 4:06:09 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/5/26 4:03:05 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dolsten Mikael sold $216,672 worth of shares (1,600 units at $135.42), decreasing direct ownership by 22% to 5,548 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/2/26 4:01:41 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials